Lefisyo (Levomethadone Hydrochloride)

Levomethadone is a mu‑opioid receptor agonist. By binding to these receptors in the brain and spinal cord, it blocks the transmission of pain signals and modifies the brain’s reward pathways, which helps relieve pain and reduces cravings and withdrawal symptoms in individuals with opioid dependence.

The dose of Lefisyo is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. No standard dosing regimen is provided here; the prescribing clinician will set the appropriate dosage and titration schedule.

Safety data for levomethadone during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare professionals should discuss the risks and benefits with the patient and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Levomethadone is the levorotatory enantiomer of methadone and generally provides similar analgesic and anti‑withdrawal effects with a potentially more favorable side‑effect profile. Both act on mu‑opioid receptors, but levomethadone may exhibit less cardiotoxicity and a more predictable pharmacokinetic profile, making it a preferred option for some clinicians.

Lefisyo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme heat. Do not store in the bathroom or near a kitchen sink to maintain its stability.

Lefisyo is administered orally, typically as a tablet or capsule taken with water. The exact form and dosing schedule are determined by the prescribing physician. Patients should follow the prescriber’s instructions regarding timing, food intake, and any required dose adjustments.

The most serious risks include respiratory depression, which can be life‑threatening, especially when combined with other central nervous system depressants. Severe hypotension, cardiac arrhythmias, and allergic reactions such as anaphylaxis are also possible. Patients should be monitored closely for signs of these adverse events, particularly during initiation and dose changes.

Lefisyo is contraindicated in individuals with known hypersensitivity to levomethadone or any component of the formulation, in patients with severe respiratory insufficiency, acute or severe asthma, and in those taking monoamine oxidase inhibitors (MAOIs) within 14 days. Caution is also advised for patients with significant hepatic or renal impairment, and it should be avoided in pregnant women unless clearly justified.